BenevolentAI achieves second major collaboration milestone with novel idiopathic pulmonary fibrosis target selected for AstraZeneca's portfolio – - Announcement represents the second collaboration milestone following the addition of a novel chronic kidney disease target to AstraZeneca's portfolio in Q1 2021BenevolentAI, a leading clinical-stage AI drug discovery company, announced that AstraZeneca has added a novel target
Odyssey Announces Agreement to Combine with BenevolentAI – Joanna Shields, Chief Executive Officer, BenevolentAI, said: "We have built BenevolentAI into a category defining business by pioneering a revolutionary approach to drug discovery and development. Our AI platform empowers scientists to leverage biomedical and experimental data at scale to understand the underlying causes of disease and develop more effective